Mustang Bio, Inc.
$0.54
$0.05 (+10.13%)
$0.49Day Range$0.54
Key Statistics
Market Cap
$4.09M
Shares Outstanding
7.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 22, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$0.49
Day High
$0.54
Day Low
$0.49
Volume
52.9K
VWAP
$0.51
Prev Close
$0.49
Transactions
--
Acc. Volume
--
About Mustang Bio, Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
PHARMACEUTICAL PREPARATIONSSIC 28344 employees95 SAWYER RD, WALTHAM, MA, 02453(781) 652-4500IPO Aug 22, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001680048
- Composite FIGI
- BBG00FXTN420
- Share Class FIGI
- BBG00FXTN439
- Ticker Root
- MBIO
- SIC Code
- 2834
About Mustang Bio, Inc. (MBIO) Stock
Mustang Bio, Inc. (MBIO) closed the 2026-09-18 session at $0.54, up 10.13% versus the previous close (+0.05). The stock opened at $0.49 and traded between $0.49 and $0.54 during that session. Session trading volume was 53K shares. The volume-weighted average price (VWAP) is $0.51.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Mustang Bio, Inc. has a market capitalization of $4.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MBIO is listed on the XNAS exchange. The company employs approximately 4 people. Mustang Bio, Inc. is headquartered in WALTHAM, MA. The recorded listing date is 2017-08-22.
On this page you can find market MBIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.